Boston seeks EU OK for drug-eluting stent
This article was originally published in Clinica
Executive Summary
Boston Scientific has taken a step forward in its efforts to market in Europe it TAXUS paclitaxel-eluting stent for reducing coronary restenosis, after submitting an application to CE-mark the product.